Aug. 7, 2009
The Susan Desmond-Hellmann era has begun.
Within hours of the former Genentech Inc. executive formally taking over as the ninth chancellor of the University of California, San Francisco, Carol Moss was named vice chancellor for university development and alumni relations.
The appointment is important because it shows that Desmond-Hellmann is quickly changing the rules — and job descriptions — as she reshapes the retirement-depleted executive ranks of UCSF.
Showing posts with label Education. Show all posts
Showing posts with label Education. Show all posts
Friday, October 30, 2009
UCSF’s Desmond-Hellmann: Not ‘the biotech chancellor’
May 8, 2009
The Susan Desmond-Hellmann era at UCSF begins Aug. 3.
Dr. Desmond-Hellmann, the former president of product development at biotech powerhouse Genentech Inc., was formally approved Thursday by the University of California Board of Regents as the next chancellor of UC, San Francisco. Pledging not to be known as “the biotech chancellor” but a champion for all segments of the school, Desmond-Hellmann, 51, will be the first woman UCSF chancellor and the first with a for-profit background.
She replaces Dr. J. Michael Bishop, a Nobel laureate who is stepping down June 30 after more than 11 years in UCSF’s top post. Bishop will remain a member of the UCSF faculty and will maintain a lab there.
Desmond-Hellmann’s base salary will be $450,000, approved by the regents on the same day they voted to raise student fees by 9.3 percent, or $750 for in-state graduate academic students.
Desmond-Hellmann faces a handful of challenges, not the least of which are replacing much of UCSF’s retiring executive team, hiring a medical school dean and increasing private philanthropy during an economic downturn.
“I expect to be out there,” she said. “People will know what the university needs and what it means and how they can contribute. … I think you’ll see more of me.”
The Susan Desmond-Hellmann era at UCSF begins Aug. 3.
Dr. Desmond-Hellmann, the former president of product development at biotech powerhouse Genentech Inc., was formally approved Thursday by the University of California Board of Regents as the next chancellor of UC, San Francisco. Pledging not to be known as “the biotech chancellor” but a champion for all segments of the school, Desmond-Hellmann, 51, will be the first woman UCSF chancellor and the first with a for-profit background.
She replaces Dr. J. Michael Bishop, a Nobel laureate who is stepping down June 30 after more than 11 years in UCSF’s top post. Bishop will remain a member of the UCSF faculty and will maintain a lab there.
Desmond-Hellmann’s base salary will be $450,000, approved by the regents on the same day they voted to raise student fees by 9.3 percent, or $750 for in-state graduate academic students.
Desmond-Hellmann faces a handful of challenges, not the least of which are replacing much of UCSF’s retiring executive team, hiring a medical school dean and increasing private philanthropy during an economic downturn.
“I expect to be out there,” she said. “People will know what the university needs and what it means and how they can contribute. … I think you’ll see more of me.”
California considers stem cell curriculum
March 27, 2009
The next chapter of California’s stem cell battle will be its textbooks.
Backed by the state Board of Education — as well as powerful lawmakers — the California Institute for Regenerative Medicine is ready to reshape the state’s science curriculum and direct a rewrite of textbooks to include sections on stem cells.
CIRM and lawmakers say it is an effort to link education with the jobs of tomorrow and keep California at the forefront of research that ultimately could deliver cures, treatments or tests for diseases ranging from diabetes to Alzheimer’s.
Opponents, however, worry the emphasis would be on morally controversial human embryonic stem cells at the expense of technologies like up-and-coming induced pluripotent stem cells.
The next chapter of California’s stem cell battle will be its textbooks.
Backed by the state Board of Education — as well as powerful lawmakers — the California Institute for Regenerative Medicine is ready to reshape the state’s science curriculum and direct a rewrite of textbooks to include sections on stem cells.
CIRM and lawmakers say it is an effort to link education with the jobs of tomorrow and keep California at the forefront of research that ultimately could deliver cures, treatments or tests for diseases ranging from diabetes to Alzheimer’s.
Opponents, however, worry the emphasis would be on morally controversial human embryonic stem cells at the expense of technologies like up-and-coming induced pluripotent stem cells.
Subscribe to:
Posts (Atom)